Second Department of Internal Medicine, University of Toyama.
Int Heart J. 2021 Jan 30;62(1):112-118. doi: 10.1536/ihj.20-437. Epub 2021 Jan 16.
Edge-to-edge repair using the MitraClip system is indicated in patients with severe mitral regurgitation (MR) who are at high risk for open-heart surgery due to comorbidity or reduced cardiac function. However, less is known about pre-procedural risk factors for mortality and morbidity following MitraClip implantation. Consecutive 25 patients with severe MR who underwent MitraClip therapy (mean age, 77 years old, 14 males) were included. Right heart catheterization and echocardiographic data before and after the procedure were collected and their prognostic impacts were investigated. Acute procedural success was 96%. At one week following MitraClip repair, left ventricular ejection fraction (LVEF) remained unchanged and left ventricular end-diastolic volume tended to be smaller. Cardiac index and mean pulmonary artery pressure (mPAP) were markedly improved following the procedure (P < 0.001 for both). In the multivariate analyses using baseline characteristics, both lower LVEF (hazard ratio 0.57, 95% confidence interval 0.30-0.89) and higher mPAP (hazard ratio 1.23, 95% confidence interval 1.06-1.56) were independently associated with post-procedural 1-year death or heart failure readmission (P < 0.05 for both). The lower LVEF and higher mPAP group had lower 1-year survival free from HF readmission compared with those without (16.7% versus 100%; P < 0.001). In conclusion, a combination of baseline mPAP and LVEF might be a useful tool in predicting post-MitraClip procedural clinical outcomes.
采用 MitraClip 系统行边对边修复适用于因合并症或心功能降低而存在开胸手术高危风险的重度二尖瓣反流(MR)患者。然而,对于 MitraClip 植入术后死亡率和发病率的术前危险因素知之甚少。本研究纳入了 25 例接受 MitraClip 治疗的重度 MR 患者(平均年龄 77 岁,男性 14 例)。收集了术前和术后的右心导管检查和超声心动图数据,并研究了它们的预后影响。急性手术成功率为 96%。MitraClip 修复后 1 周,左心室射血分数(LVEF)保持不变,左心室舒张末期容积趋于减小。心指数和平均肺动脉压(mPAP)在术后明显改善(均 P < 0.001)。在使用基线特征的多变量分析中,较低的 LVEF(危险比 0.57,95%置信区间 0.30-0.89)和较高的 mPAP(危险比 1.23,95%置信区间 1.06-1.56)均与术后 1 年死亡或心力衰竭再入院独立相关(均 P < 0.05)。与没有的患者相比,较低的 LVEF 和较高的 mPAP 组的 1 年 HF 再入院无死亡生存率较低(16.7%与 100%;P < 0.001)。总之,基线 mPAP 和 LVEF 的组合可能是预测 MitraClip 术后临床结局的有用工具。